Wilson Sonsini Goodrich & Rosati's legacy closely traces the birth and evolution of Silicon Valley.
For nearly six decades, Wilson Sonsini has represented the technology pioneers associated with virtually every milestone innovation.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
And as our clients have grown, so has our firm. Wilson Sonsini now represents many of the largest companies in the world—and thousands of the smallest ones, too.
On December 8, 2019, Rambus Inc., a premier silicon IP and chip provider, announced the completed acquisition of the silicon IP, secure protocols and provisioning business from Verimatrix, formerly Inside Secure. Wilson Sonsini Goodrich & Rosati represented Rambus in the transaction.
On December 9, 2019, Sanofi and Synthorx announced that the companies have entered into an agreement under which Sanofi will acquire Synthorx, a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion. The transaction was unanimously approved by both the Sanofi and Synthorx boards of directors. Wilson Sonsini has acted as patent counsel for Synthorx from its inception, including patent strategy, counseling, and prosecution. The Wilson Sonsini patent team was responsible for the patent diligence underlying this transaction.
On Tuesday, December 3, in response to a motion to dismiss filed by Wilson Sonsini Goodrich & Rosati, NSS Labs called off an antitrust action against cybersecurity standards development group Anti-Malware Testing Standards Organization (AMTSO) and members Symantec and ESET. Wilson Sonsini Goodrich & Rosati represented Symantec in the matter.
On November 19, Wilson Sonsini Goodrich & Rosati secured another win for Mylan as the U.S. Court of Appeals for the Federal Circuit invalidated two Sanofi patents relating to Sanofi’s Lantus vial product, upholding December 2018 decisions from the Patent Trial and Appeal Board (PTAB). In a 2-1 opinion, the majority determined that the PTAB’s findings were detailed and well supported by substantial evidence. The Federal Circuit’s decision clears the legal hurdle towards marketing of Mylan’s proposed insulin glargine vial product.
On November 19, 2019, Amazon Web Services (AWS), an Amazon.com company and global leader in infrastructure cloud computing, and Salesforce, the global leader in customer relationship management, announced an expansion of their global strategic partnership. Salesforce is introducing Service Cloud Voice, a new offering that seamlessly integrates Amazon Connect, to provide contact center agents with a complete set of tools in their workspace to deliver enhanced customer service support. Wilson Sonsini Goodrich & Rosati is representing Salesforce in the transaction.
On November 21, 2019, GSX Techedu Inc. announced the pricing of its follow-on public offering of 18,000,000 American Depositary Shares (ADSs) sold by several selling shareholders at an offering price of $14.00 per ADS for a total offering size of $252 million (or approximately $289 million if the underwriters fully exercise their options to purchase additional ADSs). Wilson Sonsini Goodrich & Rosati is representing the underwriters in the offering with respect to U.S. law. Credit Suisse Securities (USA) LLC, BofA Securities, Inc., Goldman Sachs (Asia) L.L.C., and Deutsche Bank Securities are acting as underwriters in this offering.